Clinical Pipeline
MetaVia is testing DA-1241, a GPR119 agonist, in a Phase 2a trial for metabolic dysfunction-associated steatohepatitis (MASH). The study is split into two 16-week, multicenter, randomized, double-blind, placebo-controlled trials.
metaviatx.comCrawled Nov 18, 2026
MetaVia is testing DA-1241, a GPR119 agonist, in a Phase 2a trial for metabolic dysfunction-associated steatohepatitis (MASH). The study is split into two 16-week, multicenter, randomized, double-blind, placebo-controlled trials.
Obesity is a complex disease in which excessive body fat increases due to nutrient imbalance. Obesity is a medical problem requiring interventional treatment to manage and minimize the risk of other health problems, such as diabetes, high blood pressure, and heart disease, etc.
Exploring Strategic Opportunities to Out-License Legacy Assets
Distinct Multi-target Approach: Pre-Clinical Data*
ObesityWeek 2026 – DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile Compared with Retatrutide
Vanoglipel (DA-1241) activates GPR119 in the pancreas, intestine, and liver. Non-clinical studies show it reduces lipid buildup, immune cell infiltration, and collagen production in the liver, improving MASH-related steatosis, inflammation, and fibrosis.
Endpoints - MetaVia's Obesity Candidate Cuts Liver Fat
545 Concord Avenue Suite 210 Cambridge, MA 02138 (857) 702-9600
MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).
MetaVia Inc. explains how it collects, uses, protects, and discloses user information and data on its website, including opt-out choices for personal information.